Skip to main navigation Investor Relations Corporate Overview Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who, despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com. Pulmonx Investor Presentation – November 2021 Stock Quote NASDAQ GS: LUNG $34.52 -0.49 (-1.40%) Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest News Releases Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference Nov 16, 2021 Pulmonx to Participate at Upcoming Investor Conferences Nov 03, 2021 Pulmonx Reports Third Quarter 2021 Financial Results Nov 02, 2021 View All - News View All Recent Events 33rd Annual Piper Sandler Healthcare Conference Nov 22, 2021 7:00 AM PST Stifel 2021 Virtual Healthcare Conference Nov 16, 2021 3:20 PM EST Pulmonx Q3 2021 Earnings Conference Call Nov 2, 2021 4:30 PM EDT View All Events View All News & Events Stock Information SEC Filings Corporate Governance Investor Resources ©2021 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners. | Site Designed by The Deciding Factor, Inc. GLO-EN-675-v1 September 2020 Resources About Pulmonx Management Team Company History For Patients For Physicians Contact Us Privacy Policy Terms of Use Sitemap Prescriptive Information Follow Us In order to provide you with an optimal website experience, we use cookies. By clicking "Accept" you agree to the use of cookies. Further information can be found in our privacy policy.Accept